Received Jun 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 7HG2A | — |
Priorix Inappropriate Reconstitution Technique and administration; Priorix Inappropriate Reconstitution Technique and administration; This non-serious case was reported by a nurse via call center representative and described the occurrence of wrong solution used in drug reconstitution in a 45-year-old female patient who received MMR (Priorix) (batch number 7HG2A, expiry date 01-JAN-2026) for prophylaxis. On 28-MAY-2025, the patient received Priorix. On 28-MAY-2025, an unknown time after receiving Priorix, the patient experienced wrong solution used in drug reconstitution (Verbatim: Priorix Inappropriate Reconstitution Technique and administration) and inappropriate dose of vaccine administered (Verbatim: Priorix Inappropriate Reconstitution Technique and administration). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 02-JUN-2025 Registered Nurse wanted to know if there were any concerns or consequences of given Priorix reconstituted with another diluent (from Merck's measles, mumps, and rubella vaccine) than the one provided in the box, which led wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. The reporter consented to follow up.